EVX-101 (5-HTP-based therapy)
Major Depressive Disorder (MDD) - Adjunctive Treatment
Pre-clinicalActive
Key Facts
Indication
Major Depressive Disorder (MDD) - Adjunctive Treatment
Phase
Pre-clinical
Status
Active
Company
About Evecxia Therapeutics
Evecxia Therapeutics is a private, preclinical/clinical-stage biotech founded in 2018 and based in San Diego, CA. The company is developing a novel class of drugs based on 5-HTP, the natural precursor to serotonin, to treat major depressive disorder and other mental illnesses by directly amplifying serotonin production. Its core innovation lies in proprietary drug delivery technologies designed to overcome the poor absorption and short duration of action that have historically limited 5-HTP's clinical utility. Evecxia aims to address the significant unmet need in patients who do not respond adequately to existing antidepressants like SSRIs and SNRIs.
View full company profile